Epidemiology of haemoglobin disorders in Europe: an overview

被引:126
作者
Modell, B.
Darlison, M.
Birgens, H.
Cario, H.
Faustino, P.
Giordano, P. C.
Gulbis, B.
Hopmeier, P.
Lena-Russo, D.
Romao, L.
Theodorsson, E.
机构
[1] UCL Ctr Hlth Informat & Multiprofess Educ, CHIME, London N19 5LW, England
[2] Univ Copenhagen, Herlev Hosp, Dept Haematol, DK-2730 Herlev, Denmark
[3] Univ Hosp Ulm, Dept Pediat, Ulm, Germany
[4] Inst Nacl Saude Dr Ricardo Jorge, Sector Hemoglobinopatias, Ctr Genet Humana, Lisbon, Portugal
[5] Leiden Univ, Ctr Med, Dept Human & Clin Genet, Hemoglobinopathies Lab, NL-2300 RA Leiden, Netherlands
[6] CUB Hop Erasme, Dept Clin Chem, Brussels, Belgium
[7] Rudolfstiftung Hosp, Dept Lab Med & Blood Bank, Vienna, Austria
[8] CERGM, Fac Med Marseille, Marseille, France
[9] Linkoping Univ Hosp, IBK Clin Chem, S-58185 Linkoping, Sweden
关键词
epidemiology; Europe; haemoglobin disorders; policy; prevention; screening; sickle cell; thalassaemia;
D O I
10.1080/00365510601046557
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective. As a result of global population movements, haemoglobin disorders (thalassaemias and sickle cell disorders) are increasingly common in the formerly non-indigenous countries of Northern and Western Europe and in the indigenous countries of Southern Europe. This article presents an overview of the changing picture and a method for assessing service needs. Method. Data on country of birth or ethnic origin of residents are adjusted to obtain the estimated proportions of residents and births in non-indigenous groups at risk for haemoglobin disorders in European countries. The results are combined with prevalence data in each country of origin to obtain country prevalence estimates. Service indicators (annual tests or other interventions required to ensure equitable delivery of treatment and prevention) are then derived by country. Results. Haemoglobin disorders now occur at comparable frequency throughout Northern, Western and Southern Europe. Annually, there are more affected conceptions in Northern and Western than in Southern Europe, and sickle cell disorders are more common than thalassaemias. There is growing need for health policy-makers to support motivated professionals working to develop optimal patient care, carrier diagnosis, genetic counselling and access to prenatal diagnosis throughout the Region. Conclusion. There is a strong case for pan-European collaboration on haemoglobin disorders to share policies, standards and the instruments required to support them. These include methods for needs assessment, service standards, education and information strategies and materials, and methods for evaluating service delivery.
引用
收藏
页码:39 / 69
页数:31
相关论文
共 50 条
[1]  
AKAR N, 1999, COMMUNICATION
[2]  
AMSELEM S, 1988, AM J HUM GENET, V43, P95
[3]  
ANGASTINIOTIS MA, 1981, LANCET, V1, P369
[4]  
[Anonymous], DEM YB
[5]  
[Anonymous], The thalassaemia syndromes
[6]  
Bittles AH, 1990, 90186 U MICH POP STU
[7]  
BODMER WF, 1976, GENETICS EVOLUTION M
[8]  
BOLETINI E, 1991, COMMUNICATION
[9]  
BOLETINI E, 1991, P M MED BLOOD CLUB M
[10]   Hemoglobinopathy control program in Turkey [J].
Canatan, D ;
Kose, MM ;
Ustundag, M ;
Haznedaroglu, D ;
Ozbas, S .
COMMUNITY GENETICS, 2006, 9 (02) :124-126